Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Sees Large Decline in Short Interest

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) saw a significant decrease in short interest in the month of February. As of February 13th, there was short interest totaling 125,617 shares, a decrease of 40.3% from the January 29th total of 210,405 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 20,805 shares, the short-interest ratio is presently 6.0 days. Based on an average daily trading volume, of 20,805 shares, the short-interest ratio is presently 6.0 days. Currently, 0.2% of the company’s stock are sold short.

Innate Pharma Trading Down 3.8%

IPHA stock traded down $0.07 during midday trading on Monday, reaching $1.65. 4,325 shares of the company were exchanged, compared to its average volume of 17,497. Innate Pharma has a one year low of $1.57 and a one year high of $2.63. The business has a 50-day moving average price of $1.74 and a two-hundred day moving average price of $1.90.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Innate Pharma in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in shares of Innate Pharma in the fourth quarter valued at about $162,000. OLD Mission Capital LLC bought a new stake in Innate Pharma in the 4th quarter valued at about $50,000. Finally, Millennium Management LLC bought a new position in shares of Innate Pharma during the fourth quarter worth approximately $36,000. Institutional investors own 0.16% of the company’s stock.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.